MACROGENICS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
MACROGENICS, INC. (MGNX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$44.64 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2019-11-06
- MACROGENICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2019-09-30 was -$44.64M.
- MACROGENICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2019-06-30 was -$31.73M.
- MACROGENICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2019-03-31 was -$45.01M.
- MACROGENICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2018-12-31 was -$44.65M, a 142.24% decline year-over-year.
- MACROGENICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2018 was -$171.40M.
- MACROGENICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2017 was -$19.61M.
- MACROGENICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2016 was -$58.60M.
- MACROGENICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2015 was -$20.14M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2019-09-30 | -$44.64M 10-Q · filed 2019-11-06 | -$76.38M derived: sum of 2 quarters · filed 2019-11-06 | -$121.39M 10-Q · filed 2019-11-06 | -$166.04M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2019-06-30 | -$31.73M 10-Q · filed 2019-07-31 | -$76.75M 10-Q · filed 2019-07-31 | -$121.39M derived: sum of 3 quarters · filed 2019-07-31 | -$155.44M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2019-03-31 | -$45.01M 10-Q · filed 2019-05-01 | -$89.66M derived: sum of 2 quarters · filed 2019-05-01 | -$123.71M derived: sum of 3 quarters · filed 2019-11-06 | -$166.91M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2018-12-31 | -$44.65M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$78.69M derived: sum of 2 quarters · filed 2019-11-06 | -$121.90M derived: sum of 3 quarters · filed 2019-11-06 | -$171.40M 10-K · filed 2019-02-26 | |
| 2018-09-30 | -$34.05M 10-Q · filed 2019-11-06 | -$77.25M derived: sum of 2 quarters · filed 2019-11-06 | -$126.75M 10-Q · filed 2019-11-06 | -$21.05M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2018-06-30 | -$43.20M 10-Q · filed 2019-07-31 | -$92.70M 10-Q · filed 2019-07-31 | $12.99M derived: sum of 3 quarters · filed 2019-07-31 | -$33.99M derived: sum of 4 quarters · filed 2019-07-31 | |
| 2018-03-31 | -$49.50M 10-Q · filed 2019-05-01 | $56.20M derived: sum of 2 quarters · filed 2019-05-01 | $9.21M derived: sum of 3 quarters · filed 2019-05-01 | -$31.42M derived: sum of 4 quarters · filed 2019-05-01 | |
| 2017-12-31 | $105.69M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $58.71M derived: sum of 2 quarters · filed 2019-02-26 | $18.08M derived: sum of 3 quarters · filed 2019-02-26 | -$19.61M 10-K · filed 2019-02-26 | -$19.65M 10-K · filed 2018-02-27 |
| 2017-09-30 | -$46.99M 10-Q · filed 2018-11-07 | -$87.62M derived: sum of 2 quarters · filed 2018-11-07 | -$125.30M 10-Q · filed 2018-11-07 | -$160.18M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-06-30 | -$40.63M 10-Q · filed 2018-08-07 | -$78.31M 10-Q · filed 2018-08-07 | -$113.19M derived: sum of 3 quarters · filed 2019-02-26 | -$147.08M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-03-31 | -$37.68M 10-Q · filed 2018-05-07 | -$72.56M derived: sum of 2 quarters · filed 2019-02-26 | -$106.45M derived: sum of 3 quarters · filed 2019-02-26 | -$65.98M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2016-12-31 | -$34.88M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$68.77M derived: sum of 2 quarters · filed 2019-02-26 | -$28.30M derived: sum of 3 quarters · filed 2019-02-26 | -$58.60M 10-K · filed 2019-02-26 | |
| 2016-09-30 | -$33.89M 10-Q · filed 2017-11-08 | $6.58M derived: sum of 2 quarters · filed 2017-11-08 | -$23.72M 10-Q · filed 2017-11-08 | -$52.18M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $40.47M 10-Q · filed 2017-08-02 | $10.16M 10-Q · filed 2017-08-02 | -$18.29M derived: sum of 3 quarters · filed 2018-02-27 | -$33.73M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-03-31 | -$30.31M 10-Q · filed 2017-05-03 | -$58.76M derived: sum of 2 quarters · filed 2018-02-27 | -$74.20M derived: sum of 3 quarters · filed 2018-02-27 | -$95.58M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2015-12-31 | -$28.46M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$43.90M derived: sum of 2 quarters · filed 2018-02-27 | -$65.27M derived: sum of 3 quarters · filed 2018-02-27 | -$20.14M 10-K · filed 2018-02-27 | |
| 2015-09-30 | -$15.44M 10-Q · filed 2016-11-02 | -$36.82M derived: sum of 2 quarters · filed 2016-11-02 | $8.31M 10-Q · filed 2016-11-02 | ||
| 2015-06-30 | -$21.38M 10-Q · filed 2016-08-03 | $23.75M 10-Q · filed 2016-08-03 | |||
| 2015-03-31 | $45.13M 10-Q · filed 2016-05-04 | ||||
| 2014-12-31 | -$38.31M 10-K · filed 2017-02-28 | ||||
| 2013-12-31 | -$261.00K 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |